## DT12 Rec'd PCT/PTO 1 1 MAR 2005

MODIFIED PTO/SB/08 (08-00) Approved for use through 10/31/2002. OMB 0651-0031

: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, r

U.S. Patent and Trademark ons are required to respond to a collection of inform

nless it contains a valid OMB control

Substitute for form 1449B/PTO INFORMATION DISCLOSURE				Complete if Known 159766		
			Application Number	Unassigned LUIJ L		
	STATEMEN	T BY APPLICANT	Filing Date	03/11/2005		
	Data Cubmitt	ed: March 11, 2005	First Named Inventor	Christophe de ROMEUF et al.		
	Date Submitte	ed. March 11, 2005	Group Art Unit	Onassigned 1644		
	(use as many s	sheets as necessary)	Examiner Name	- Uncooigned Chun Dahle		
Sheet	1	of 2	Attorney Docket Number	065691-0389		

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document			Date of Publication of	Pages, Columns, Lines, Where Relevant
		Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear
/C.D./	A1	6,180,377	B1	BODMER et al.	01/30/2001	
***			-			

FOREIGN PATENT DOCUMENTS									
Examiner Initials*	Cite No.1	Fore Office <sup>3</sup>	eign Patent D Number <sup>4</sup>	ocument Kind Cod		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
000000000000000000000000000000000000000	~ <u>A</u> 2	<b></b>	<i>4/77</i> +8+		<b>44</b>		48/48/2084	000000000000000000000000000000000000000	0000000000
									+
				-					
									<u> </u>

	NON PATENT LITERATURE DOCUMENTS							
	Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>				
		А3	CARTRON et al., "Therapeutic Activity of Humanized anti-CD20 Monoclonal Antibody and Polymorphism in					
****			XP-001193741, & 43 <sup>rd</sup> Annual Meeting of the American Society of Hematology, July 11, 2001.					
		A4	SHIELDS et al., "Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human					
0000000	000000000000000000000000000000000000000	000000000000000	PcyammaRiii and Antibody-Dependent Cellular Toxicity," Journal of Biological Chemistry, American Society of Biological Chemists, Vol. 277, No. 30, July 26, 2002, pp. 26733-26740, XP-002964542.	00000000				
		A5	SHINKAWA et al., "The Absence of Fucose But Not The Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-Type Oligosaccharides Shows The Critical Role of Enhancing Antibody-Dependent Cellular Cytotoxicity." Journal of Riological Chemistry. American Society of Biological					
00000000	500000000000000000000000000000000000000	000000000000000000000000000000000000000	Chemists, Vol. 278, No. 5, January 31, 2003, pp. 3466-3473, XP-002965857.	>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>				
		A6	VIDOVIC et al., "Selective Apoptosis of Neoplastic cells by the HLA-DR-Specific Nomoclonal Antibody," Cancer Letters, Vol. 128, No. 2, June 19, 1998, pp. 127-135, XP-000857331					
0000000	900000000000000000000000000000000000000	A7	WRIGHT et al., "Effect of Glycosylation on Antibody Function: Implications for Genetic Engineering," Trends in Biotechnology Elsevier Publications Vol. 15. No. 1, 1997, pp. 26-32, XP-004016809.	>>>>>>>				
		<u> </u>						

Examiner Signature	/Chun Dahle/	Date Considered	07/17/2008

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<sup>1</sup> Unique citation designation number. 2See attached Kinds of U.S. Patent Documents, 3Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.